+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
ID07458906

Evaluating DLL3-Targeted PETCT Imaging for Detecting Neuroendocrine Carcinoma Tumors

Led by The First Affiliated Hospital of Xiamen University · Updated on 2026-09-25

80

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the diagnostic value of DLL3-targeted PETCT imaging in patients with suspected or confirmed neuroendocrine carcinoma. The study aims to compare this new imaging technique with conventional imaging methods like CT, MRI, or 18F-FDG PETCT to see if it can better detect tumor lesions and evaluate tumor DLL3 expression. Participants receive a single intravenous injection of a DLL3-targeted probe followed by PETCT imaging. This imaging is done alongside conventional imaging for initial assessment or detection of metastases or recurrence. Tumor uptake will be measured and compared to immunohistochemistry results to assess the feasibility of visualizing DLL3 expression in tumors. Researchers will record and compare the number of tumor lesions detected by both imaging methods. During the study, participants will be monitored for changes in vital signs within one day after tracer administration and radiation absorbed dose in normal organs over one year. The study will also assess the correlation between tumor DLL3 expression and tracer uptake. Participants will undergo scheduled imaging and evaluations to measure these outcomes, with overall participation lasting up to one year.

CONDITIONS

Brief Title

DLL3-Targeted PET/CT in Neuroendocrine Carcinoma

Research Team

L

Liang Zhao

H

Haojun Chen

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here